JP2023548429A5 - - Google Patents
Info
- Publication number
- JP2023548429A5 JP2023548429A5 JP2023550714A JP2023550714A JP2023548429A5 JP 2023548429 A5 JP2023548429 A5 JP 2023548429A5 JP 2023550714 A JP2023550714 A JP 2023550714A JP 2023550714 A JP2023550714 A JP 2023550714A JP 2023548429 A5 JP2023548429 A5 JP 2023548429A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- compound
- acceptable salt
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206645.2 | 2020-11-10 | ||
| EP20206645 | 2020-11-10 | ||
| PCT/EP2021/081162 WO2022101227A1 (en) | 2020-11-10 | 2021-11-09 | [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548429A JP2023548429A (ja) | 2023-11-16 |
| JP2023548429A5 true JP2023548429A5 (enExample) | 2024-11-18 |
Family
ID=73288427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550714A Abandoned JP2023548429A (ja) | 2020-11-10 | 2021-11-09 | パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220168242A1 (enExample) |
| EP (1) | EP4243801A1 (enExample) |
| JP (1) | JP2023548429A (enExample) |
| KR (1) | KR20230106659A (enExample) |
| CN (1) | CN116685314A (enExample) |
| AR (1) | AR124036A1 (enExample) |
| AU (1) | AU2021378472A1 (enExample) |
| CA (1) | CA3198266A1 (enExample) |
| TW (1) | TW202233169A (enExample) |
| WO (1) | WO2022101227A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3268423A1 (en) * | 2022-09-21 | 2024-03-28 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts thereof |
| GB202312055D0 (en) | 2023-08-07 | 2023-09-20 | Ipsen Biopharm Ltd | Pharmaceutical compositions |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101203511A (zh) | 2005-06-23 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| JP6245983B2 (ja) * | 2010-08-11 | 2017-12-13 | ドレクセル ユニバーシティ | パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト |
| US9006227B2 (en) | 2011-04-19 | 2015-04-14 | Integrative Research Laboratories Sweden Ab | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission |
| EP2858649B1 (en) * | 2012-06-11 | 2019-10-23 | Psychogenics Inc. | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments |
| CA2986891C (en) * | 2015-05-26 | 2022-01-04 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Compositions for use in treating parkinson's disease and related disorders |
| WO2020110128A1 (en) * | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| US12275694B2 (en) * | 2019-05-24 | 2025-04-15 | Irl 790 Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
-
2021
- 2021-11-09 JP JP2023550714A patent/JP2023548429A/ja not_active Abandoned
- 2021-11-09 CA CA3198266A patent/CA3198266A1/en active Pending
- 2021-11-09 KR KR1020237019294A patent/KR20230106659A/ko active Pending
- 2021-11-09 AR ARP210103113A patent/AR124036A1/es not_active Application Discontinuation
- 2021-11-09 CN CN202180089407.4A patent/CN116685314A/zh active Pending
- 2021-11-09 EP EP21799308.8A patent/EP4243801A1/en active Pending
- 2021-11-09 AU AU2021378472A patent/AU2021378472A1/en not_active Abandoned
- 2021-11-09 US US17/454,110 patent/US20220168242A1/en not_active Abandoned
- 2021-11-09 WO PCT/EP2021/081162 patent/WO2022101227A1/en not_active Ceased
- 2021-11-09 TW TW110141661A patent/TW202233169A/zh unknown
-
2023
- 2023-09-06 US US18/461,791 patent/US20240148674A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101636145B (zh) | 长期24小时经肠给予左旋多巴/卡比多巴 | |
| JP2018513188A5 (enExample) | ||
| CN117177743A (zh) | 包含依维莫司和安森司群的组合 | |
| JP2023535744A5 (enExample) | ||
| CN107519159A (zh) | 复方组合物 | |
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| AU2012302106B2 (en) | Use of organic compound for the treatment of noonan syndrome | |
| JP2019218379A5 (enExample) | ||
| CN103370066A (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| JP2024545496A5 (enExample) | ||
| JP2022519007A5 (enExample) | ||
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| JP2024516003A5 (enExample) | ||
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| CN106507666A9 (zh) | 1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途 | |
| JP2022508236A (ja) | びらん性変形性手関節症の治療のためのモンテルカスト | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| CN1223338C (zh) | 盐酸西替利嗪凝胶剂 | |
| JP2024518804A5 (enExample) | ||
| WO2022183493A1 (zh) | 一种多酚类化合物的应用 | |
| EP4081210B1 (en) | Pharmaceutical composition of casr modulators and methods and uses thereof | |
| JP2024541770A5 (enExample) | ||
| CN1378451A (zh) | 用于治疗银屑病的药物组合物 | |
| CN107970248A (zh) | 异甘草酸在制备治疗高血压药物中的用途 |